Immune checkpoint blockade (ICB) therapies have achieved clinical benefit, but most
'immune-cold'solid tumors are not responsive. The diversity of immune evasion mechanisms …

Immune checkpoint inhibitors (ICIs) induce a durable response in a wide range of tumor
types, but only a minority of patients outside these 'responsive'tumor types respond, with …

Immune checkpoint inhibitors have revolutionized the treatment landscape for a number of
cancers over the last few decades. Nevertheless, a majority of patients still do not benefit …

Immunotherapies are the most rapidly growing drug class and have a major impact in
oncology and on human health. It is increasingly clear that the effectiveness of …

Immunotherapy includes immune checkpoint inhibitors (ICI) such as antibodies targeting
cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) or the programmed cell death …

Therapeutic monoclonal antibodies targeting immune checkpoints (ICPs) have changed the
treatment landscape of many tumors. However, response rate remains relatively low in most …

Cancer patients with low or absent pre-existing anti-tumour immunity (“cold” tumours)
respond poorly to treatment with immune checkpoint inhibitors (ICPI). In order to render …

Immunotherapy, represented by immune checkpoint inhibitors (ICIs), has greatly improved
the clinical efficacy of malignant tumor therapy. ICI-mediated antitumor responses depend …

Background Different types of tumors have varying susceptibility to immunotherapy and
hence require different treatment strategies; these cover a spectrum ranging from 'hot'tumors …

Notable advances have been achieved in the treatment of cancer since the advent of
immunotherapy, and immune checkpoint inhibitors have shown clinical benefit across a …